We would like to show you a description here but the site won’t allow us. The price will be higher if you have a deductible, are in the Medicare coverage gap, are using non-formulary drugs, or you're paying a percentage instead of a flat copay. Sometimes, the pharmacy can see the specifics of why your insurance determined the cost to be what it is, but for the most detailed information, have the pharmacy keep the. Call (844) MS-COPAY (844-672-6729) 9 a.m.–8 p.m. ET, Monday through Friday (except major holidays) For questions about OCREVUS, please call (844) OCREVUS (844-627-3887). Fax (855) MS-COPAY (855-672-6729) OCREVUS ® and its logo are. Welcome to the CPS Portal. Enter Your Login Information. Email Address: Password. Forgot Password?
Important Safety Information
Contraindications
None.
Warnings and Precautions
Infusion-Related Reactions (IRRs). MONJUVI can cause IRRs, including chills, flushing, dyspnea, and hypertension. Premedicate patients and monitor frequently during infusion. Based on the severity of the IRR, interrupt or discontinue MONJUVI and institute appropriate medical management.
Myelosuppression. MONJUVI can cause serious or severe myelosuppression, including neutropenia, thrombocytopenia, and anemia. Monitor complete blood counts (CBC) prior to administration of each treatment cycle and throughout treatment. Monitor patients with neutropenia for signs of infection. Consider granulocyte colony-stimulating factor administration. Withhold MONJUVI based on the severity of the adverse reaction. Refer to the lenalidomide prescribing information for dosage modifications.
Infections. Fatal and serious infections, including opportunistic infections, occurred in patients during treatment with MONJUVI and following the last dose. 73% of the 81 patients developed an infection. The most frequent infections were respiratory tract infection, urinary tract infection, bronchitis, nasopharyngitis and pneumonia. Grade 3 or higher infection occurred (30% of 81 patients). The most frequent grade 3 or higher infection was pneumonia. Infection-related deaths were reported (2.5% of 81 patients). Monitor patients for signs and symptoms of infection and manage infections as appropriate.
Embryo-Fetal Toxicity. Based on its mechanism of action, MONJUVI may cause fetal B-cell depletion when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus and women of reproductive potential to use effective contraception during treatment with MONJUVI and for at least 3 months after the last dose. The combination of MONJUVI with lenalidomide is contraindicated in pregnant women. Refer to the lenalidomide prescribing information on use during pregnancy.
Adverse Reactions
The most common adverse reactions (≥20%) were neutropenia (51%), fatigue (38%), anemia (36%), diarrhea (36%), thrombocytopenia (31%), cough (26%), pyrexia (24%), peripheral edema (24%), respiratory tract infection (24%), and decreased appetite (22%).
Indications & Usage
MONJUVI (tafasitamab-cxix), in combination with lenalidomide, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to MORPHOSYS US INC. at (844) 667-1992.
Please see the full Prescribing Information for additional Important Safety Information.
My Copay Is $40
Requesting a new Co-Pay Card or activating an existing one is simple:
- You will be guided through a simple activation process
- Your eligibility will be confirmed
- You can also replace a lost or stolen card
Have questions about your NEXLETOL & NEXLIZET Co-Pay Card?
Call 1-855-699-8814 (8:00AM-8:00PM ET, Monday-Friday,
excluding holidays).
Looking for additional helpful resources?
*For privately or commercially insured patients. Restrictions apply.
See Terms and Conditions.
Eligibility Requirements
A patient may be eligible for the NEXLETOL & NEXLIZET Co-Pay Card if they meet the eligibility criteria below:
- must be at least 18 years of age, AND
- has a valid prescription for NEXLETOL or NEXLIZET, AND
- has commercial prescription drug insurance, AND
- is a resident of the United States, including the District of Columbia but excluding territories (such as Puerto Rico and the US Virgin Islands), AND
- is not enrolled in any state-, federal-, or government-funded healthcare program, including but not limited to Medicare, Medicaid, Medigap, TRICARE of the Department of Defense, or the Department of Veterans Affairs (VA) healthcare program (collectively referred to as “Government Program”).
Should a patient have any change in insurance coverage or become enrolled in a Government Program during their enrollment in the NEXLETOL & NEXLIZET Co-Pay Card program, they must inform a NEXLETOL & NEXLIZET Co-Pay Card program representative and will no longer be eligible for the NEXLETOL & NEXLIZET Co-Pay Card program. Also, if a patient is enrolled in a Government Program, they may not use the NEXLETOL & NEXLIZET Co-Pay Card program even if they elect to be processed as a commercial or discount insurance plan patient.
My Copay Assistance
See more details.